Unichem Laboratories Ltd

Unichem Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 Feb 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 06 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

The Sensex advanced 1.35% on 29 Apr 2026, yet Unichem Laboratories Ltd outpaced the broader market with an 8.28% gain, touching an intraday high of Rs 401.45. This 5.43-percentage-point outperformance over the Pharmaceuticals & Biotechnology sector signals a distinctly stock-specific rally rather than a market-wide lift.

Unichem Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 April 2026, providing investors with the latest insights into its performance and outlook.

Unichem Laboratories Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, despite ongoing sector headwinds and a challenging price performance relative to the broader market. This recalibration in price-to-earnings and price-to-book value metrics offers investors a fresh perspective on the stock’s price attractiveness within the Pharmaceuticals & Biotechnology sector.

The Sensex declined 0.91% on 23 Apr 2026 while Unichem Laboratories Ltd surged 7.0%, reaching an intraday high of Rs 392.2. This 0.62 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a stock-specific strength amid a broadly weak market environment.

The Sensex declined by 0.79% on 22 Apr 2026, yet Unichem Laboratories Ltd surged 8.84%, outperforming its Pharmaceuticals & Biotechnology sector by nearly 7 percentage points. This sharp single-session gain rewrites the short-term narrative for the small-cap stock, raising the question of whether this is a genuine recovery or a technical bounce within a broader downtrend.

Unichem Laboratories Ltd has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. Despite a recent mild improvement in price momentum, the pharmaceutical company’s stock continues to face headwinds, with its overall technical grade remaining in the sell category. This article analyses the latest technical indicators, price movements, and comparative returns to provide a comprehensive view of Unichem’s current market positioning.

Unichem Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook.

Unichem Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 April 2026, providing investors with the latest insights into the company’s performance and outlook.

While the broader market shows signs of recovery, Unichem Laboratories Ltd has continued its downward trajectory, hitting a fresh 52-week low of Rs 280 on 30 Mar 2026. This decline contrasts sharply with the Sensex’s modest rebound, underscoring stock-specific pressures that have weighed heavily on the pharmaceutical company’s shares.

Unichem Laboratories Ltd’s stock price declined sharply on 27 Mar 2026, hitting a new 52-week low of Rs.291.2. This marks a significant drop amid broader market weakness, with the stock underperforming its sector and major indices on the day.

Unichem Laboratories Ltd’s share price declined to a fresh 52-week low of Rs.297 on 24 March 2026, marking a significant downturn amid broader market pressures and company-specific financial concerns. The stock has underperformed its sector and benchmark indices, reflecting ongoing challenges in profitability and debt servicing.

Unichem Laboratories Ltd’s stock price declined to a fresh 52-week low of Rs.302.15 on 23 March 2026, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector and broader market weakness. The stock’s fall aligns with a sector decline and a sharply lower Sensex, underscoring the challenging environment for the company.

Unichem Laboratories Ltd is rated 'Sell' by MarketsMOJO. This rating was last updated on 16 February 2026, reflecting a change in the company’s assessment. However, all fundamentals, returns, and financial metrics discussed below are current as of 23 March 2026, providing investors with an up-to-date view of the stock’s position.

Unichem Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Unichem Laboratories Ltd’s share price declined to a fresh 52-week low of Rs.304.25 today, marking a significant downturn amid broader market gains. The stock has underperformed its sector and key indices, reflecting ongoing pressures on the company’s financial and market performance.

Unichem Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.